Celsion
Corporation (CLSN) is a clinical-stage biopharmaceutical company
focused on the development of innovative cancer therapies. The
company's lead product candidate is ThermoDox, a heat-activated
liposomal encapsulation of doxorubicin that is being developed for the
treatment of liver cancer.
ThermoDox is designed to release the
chemotherapy drug doxorubicin specifically within the tumor, using
heat generated by a non-invasive ultrasound device. This approach is
intended to enhance the efficacy of doxorubicin while minimizing its
toxic effects on healthy tissues.
In addition to ThermoDox,
Celsion Corporation is also developing GEN-1, an immunotherapy product
candidate that is being studied in combination with standard
chemotherapy for the treatment of ovarian cancer. GEN-1 is designed to
stimulate the immune system to attack cancer cells, while also
enhancing the effects of chemotherapy.
Celsion Corporation was
founded in 1982 and is headquartered in Lawrenceville, New Jersey. The
company has a small team of employees and collaborates with academic
and industry partners to advance its drug development programs. As of
2021, the company is focused on advancing ThermoDox and GEN-1 through
clinical trials and seeking regulatory approval for these drugs.
Celsion Corporation faces significant competition from other companies
developing cancer therapies, particularly in the areas of
immunotherapy and targeted
|
